Microbot Medical’s ATM Program: A High-Dilution Risk for Shareholders

Microbot Medical Inc. (NASDAQ: MBOT) faces a substantial dilution risk due to its at-the-market (ATM) equity offering program. With $39.2M in remaining ATM capacity and a market cap of $136.3M, the ATM represents 28.8% of the company’s total market value. This level of unused authorization signals significant potential for share dilution, which could erode shareholder value if tapped aggressively.

### Understanding the ATM Risk

An ATM program allows companies to sell shares continuously at market price, providing liquidity but often at the cost of dilution. For small-cap biotechs like MBOT, which operates in the high-risk, high-cost life sciences sector, ATM reliance can become a double-edged sword. While the program offers flexibility to fund operations or clinical trials, excessive use typically signals financial strain and a lack of near-term profitability.

MBOT’s ATM-to-market-cap ratio of 28.8% ranks among the highest observed in the small-cap biotech space. To contextualize this: if the company were to fully exhaust its ATM capacity, it would issue shares equivalent to ~28.8% of its current market value, directly reducing existing shareholders’ ownership percentages and potentially depressing earnings per share (EPS). Even partial use of the ATM—say, $20M of the $39.2M—would still represent ~14.6% of the company’s market cap, a material dilutive event for a firm with a sub-$150M valuation.

### Implications for Shareholders

The dilution risk is amplified by MBOT’s profile as a pre-revenue company. Its business model hinges on advancing robotic medical technologies through clinical trials—a process that demands heavy R&D spending. Without a near-term path to profitability, the company is likely to remain dependent on equity financing, with the ATM serving as a convenient (but dangerous) funding tool.

Moreover, the ATM’s size suggests MBOT may not have adequately constrained its dilution risk. A program exceeding 25% of market cap is rarely sustainable for small-cap biotechs, as repeated share issuances can trigger investor flight and volatility. The company’s ability to avoid over-reliance on the ATM will be critical to maintaining shareholder trust.

### What to Watch

Investors should closely monitor the following:

• ATM Utilization: Track press releases or SEC filings (e.g., 8-Ks) for updates on share sales under the ATM. Even partial use of the $39.2M capacity could trigger meaningful dilution.
• Clinical Milestones: Progress (or delays) in MBOT’s pipeline, particularly its robotic endoscopy platform, will influence its need for capital. Positive data could reduce dilution risk by attracting partnerships or IPO interest.
• New ATM Authorizations: If MBOT seeks to expand its ATM capacity in the future, the dilution risk will escalate further. Shareholders should scrutinize any new equity programs.

In summary, MBOT’s ATM program represents a high-risk, high-reward dynamic. While it provides financial flexibility, the $39.2M remaining capacity threatens to destabilize shareholder